<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005641</url>
  </required_header>
  <id_info>
    <org_study_id>ELBA</org_study_id>
    <secondary_id>EudraCT number: 2008-007946-67</secondary_id>
    <nct_id>NCT01005641</nct_id>
  </id_info>
  <brief_title>ELBA: Exemestane and Lapatinib in Advanced Breast Cancer</brief_title>
  <acronym>ELBA</acronym>
  <official_title>Phase II Multicentered Study of Exemestane and Lapatinib in Advanced Hormone-responsive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aromatase inhibitors are the standard treatment for hormone responsive advanced breast&#xD;
      cancer. The combination of the aromatase inhibitor exemestane with with another breast cancer&#xD;
      drug that blocks epidermal growth factor receptor (EGFR) and Erb-2 activity (lapatinib) is&#xD;
      being studied for the possibility of improving response to therapy, and delaying resistance&#xD;
      to endocrine therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recommended dose of lapatinib will be determined in the first part of the study. In the&#xD;
      second part of the study, patients will receive the recommended dose of lapatinib and&#xD;
      exemestane daily, taken orally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study not started for administrative reasons&#xD;
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recommended dose of lapatinib given in combination with standard dose of exemestane in patients with advanced hormone-responsive breast cancer</measure>
    <time_frame>one month after dose selection for each of 3 possible dose levels</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>proportion of patients free from progression</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related toxicity</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response</measure>
    <time_frame>at 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic role of molecular markers and circulating tumor cells</measure>
    <time_frame>at 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phase II</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>25 mg daily</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib</intervention_name>
    <description>taken orally, daily, at dose recommended after dose finding part of study</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of breast cancer&#xD;
&#xD;
          -  Indication for hormonal therapy (ER and/or PgR positive)&#xD;
&#xD;
          -  Stage IV disease&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  Postmenopausal status (patients treated with LHRH analogs are eligible for the Phase&#xD;
             II part of the study)&#xD;
&#xD;
          -  At least one target or non-target lesion according to RECIST criteria&#xD;
&#xD;
          -  ECOG Performance Status 0-2&#xD;
&#xD;
          -  Adequate bone marrow (neutrophils &gt; or = 1.500/mm³, platelets &gt; or = 100.000/mm³ and&#xD;
             hemoglobin &gt; or = 9 g/dl), hepatic (GOT, GPT &lt; 2.5 e bilirubin &lt;1.25 times the value&#xD;
             of upper normal limit) and renal (creatinine &lt; 1.25 times the value of upper normal&#xD;
             limit) function&#xD;
&#xD;
          -  Adequate cardiac function (FEVS &gt; or = 50%)&#xD;
&#xD;
          -  Able to take oral medications&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous hormone therapy for metastatic disease&#xD;
&#xD;
          -  More than one line of chemotherapy for metastatic disease (first line chemotherapy is&#xD;
             permitted)&#xD;
&#xD;
          -  Symptomatic cerebral metastases&#xD;
&#xD;
          -  Planned concomitant radiation therapy in the first month of therapy (for those&#xD;
             patients participating in the dose finding phase of the study)&#xD;
&#xD;
          -  Previous therapy with exemestane, including as adjuvant therapy (previous therapy with&#xD;
             non-steroidal aromatase inhibitors is permitted)&#xD;
&#xD;
          -  Previous or concurrent malignancy in past 5 years (excluding adequately treated basal&#xD;
             cel or spinocellular skin cancer and in situ carcinoma of the cervix)&#xD;
&#xD;
          -  Treatment with experimental pharmacologic therapy within 4 weeks of enrollment in the&#xD;
             study&#xD;
&#xD;
          -  Unable or unwilling to provide signed informed consent&#xD;
&#xD;
          -  Any concurrent illness that would, in the Investigator's opinion, contraindicate the&#xD;
             use of the study drugs.&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Assumption of CYP3A4 inhibitors or inducers (ketoconazole, itraconazole, fluconazole,&#xD;
             macrolide antibiotics, antidepressives, calcium-antagonists, cimetidine,&#xD;
             carbamazepine, phenytoin, barbiturates, rifampicin e glucocorticoids)&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Unable to comply with follow-up&#xD;
&#xD;
          -  Active hepatobiliary disease (with the exception of Gilbert's syndrome, asymptomatic&#xD;
             biliary calculi, hepatic metastases or stabile chronic hepatopathy)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea de Matteis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Division of Medical Oncology C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Clinical Trials Office</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Morabito, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Normanno, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Luca ASL SA 3</name>
      <address>
        <city>Vallo della Lucania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2009</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <name_title>Francesco Perrone</name_title>
    <organization>NCI Naples</organization>
  </responsible_party>
  <keyword>advanced breast cancer</keyword>
  <keyword>hormone-responsive</keyword>
  <keyword>metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

